Compare Biogen Inc (BIIB) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Cadence Design Systems Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Cadence Design Systems Inc trades at $326.99 (market cap $90.20B). The key difference: Cadence Design Systems Inc is far larger — about 3× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | CDNS | |
|---|---|---|
Market Cap | $30.13B | $90.20B |
Sector | Health | Technology |
52-Week High | $216.63 | $416.39 |
52-Week Low | $128.93 | $265.66 |
Enterprise Value | $37.20B | $91.41B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
